All Names: Niratinib,Nerlynx,Hernix
Indications:1. Extended Adjuvant Treatment of Early-Stage Breast Cancer; 2. Advanced or Metastatic Breast Cancer
Manufacturer:Beacon Medicines, Bangladesh
Customs Clearance Procedure:If the customs requires the package for customs clearance, please pay the customs clearance fee according to the content of EMS SMS and customs regulations.
INDICATIONS AND USAGE(适应症)
Extended Adjuvant Treatment of Early-Stage Breast Cancer
NERLYNX as a single agent is indicated for the extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer, to follow adjuvant trastuzumab based therapy.
Advanced or Metastatic Breast Cancer
NERLYNX in combination with capecitabine is indicated for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.
DOSAGE(服用剂量)
Extended Adjuvant Treatment of Early-Stage Breast Cancer
The recommended dose of NERLYNX is 240 mg (six tablets) given orally once daily, with food, continuously until disease recurrence or for up to one year.
Advanced or Metastatic Breast Cancer
The recommended dose of NERLYNX is 240 mg (six tablets) given orally once daily with food on Days 1–21 of a 21-day cycle plus capecitabine (750 mg/m 2 given orally twice daily) on Days 1–14 of a 21-day cycle until disease progression or unacceptable toxicities.
ADVERSE REACTIONS(不良反应)
Diarrhea
Hepatotoxicity
For full information, please refer to:
https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/d1e41dcf-e82a-47c2-a0ad-6c6eef621834/spl-doc?hl=nerlynx
Hernixinformation
No information yet!!!